2025 has been a productive year in gut microbiome research, spanning metabolic health, neurogastroenterology, immune modulation, and precision nutrition. In this ‘Year in Review’ article, the GMFH editing team describes their pick of the top GMFH-covered advances in 2025, outlining their impact in the clinical setting and implications for current and future research.
Digestive Disease Week 2025 featured recent basic, translational, and clinical research into the microbiome. Find out more about the main takeaways relevant for your clinical practice selected by GMFH editors.
After two decades of scientific exploration, the human microbiome has emerged as a critical determinant of health and disease. Fueled by multi-omics technologies and machine learning, the field has advanced from correlation-based observations to establishing causal relationships. This article presents recent and compelling examples of microbiome-based treatments that are ripe for clinical adoption and discusses challenges and opportunities facing the field based on expert interviews conducted by the GMFH team.
Clinical translation of microbiome research: takeaways from the 2025 GMFH Summit
16 May 2025by Andreu Prados
The 13th Gut Microbiota for Health World Summit took place 15-16 March 2025 in Washington, D.C., and it focused on advances in microbiome research to diagnose, prevent, and manage gastrointestinal and extra-intestinal conditions. Find out more about the most valuable takeaways from the event.
Patients with metabolic liver diseases may benefit from supplements of a common gut bacterium, a small study suggests.
Differences in the gut microbiota in patients with IBD compared to healthy controls suggest that probiotics may be of help. This article takes an in-depth look into the rationale of using probiotics for IBD and summarizes the evidence from recent clinical guidelines for the use of probiotics in Crohn’s disease, ulcerative colitis and pouchitis.
Can probiotics aid in treating bacterial vaginosis and vulvovaginal candidiasis?
14 Jun 2023by Andreu Prados
Probiotics are commonly used in clinical practice for digestive ailments. Some clinical trials also support the use of specific probiotics, taken orally or vaginally, for restoring the vaginal microbiota and managing bacterial vaginosis and vulvovaginal candidiasis. Here’s what we know.
The translational potential of microbiome research for human health and disease: takeaways from the 2023 GMFH Summit
28 Apr 2023by Andreu Prados, Joël Doré
The 11th Gut Microbiota for Health World Summit focused on emerging gut microbiome-targeted treatments in digestive, immune and cardiometabolic health. This post highlights the major take-aways from the conference and explores how they might impact clinical practice in the foreseeable future.
Can probiotics have anti-inflammatory effects worth considering in chronic intestinal diseases?
28 Sep 2022by Andreu Prados
Inflammation has been involved in the onset of chronic diseases. Probiotics emerge as a potential dietary tool for managing those conditions, partly through their role in immune system modulation and the anti-inflammatory response. Find out what is known about the anti-inflammatory effects of probiotics and their potential applications at the bedside.
The brain-gut-microbiota axis involves different routes of communication and can be targeted to influence brain and behavior
20 May 2022by Andreu Prados
The gut-brain connection is largely shaped by the composition and function of gut-dwelling microbial communities. This review article addresses how the brain and gut communicate and considers potential psychobiotic therapies.
